证券研究报告 2025 年 12 月 07 日 湘财证券研究所 行业研究 疫苗行业周报 继续关注流感需求与创新进展 核心要点： 国内外疫苗动态 （1）瑞吉生物：冻干带状疱疹 mRNA 疫苗（RH110）启动 II 期临床。近日， 瑞吉生物自主研发的冻干带状疱疹 mRNA 疫苗 RH110 正式启动 II 期临床试 验。该项试验采用随机、双盲、对照的多中心设计，旨在评价 RH110 在 40 岁 及以上受试者中的免疫原性与安全性，主要终点指标包括：第 2 剂疫苗接种 后第 30 天，抗 gE 抗原特异性血清抗体和抗 VZV 抗原特异性血清抗体几何平 均滴度和阳转率。RH110 疫苗为注射用冻干制剂，针对水痘-带状疱疹病毒引 起的带状疱疹进行预防，在已完成的Ⅰ期临床试验中，RH110 显示出优异的 安全性和耐受性。（来源：瑞吉生物） 相关研究： 1. 《流感活动度继续攀升至近 三年同期高位，继续关注结构性 机会》20251123 2. 《疫苗企业国际化与研发继 续实现突破，冬季防控压力持续 凸显》20251130 国家流感中心发布的中国流感监测周报显示，2025 年 11 月 24 日-11 月 30 日， 南、 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [3][10][42] Core Insights - The rare earth magnetic materials industry has shown a price increase of 3.47% this week, outperforming the benchmark (CSI 300) by 2.19 percentage points. The industry valuation (TTM P/E) has risen by 2.37 times to 74.16, currently at 87.3% of its historical percentile [5][12] - Supply tightening in the rare earth sector is supporting price increases, while heavy rare earth prices continue to decline. The market is experiencing a mixed demand scenario, with stable demand from downstream neodymium-iron-boron enterprises and expectations of increased exports [9][41] - The report indicates that the short-term outlook for rare earth prices is expected to remain strong due to supply constraints, low market inventory, and stable downstream demand, alongside long-term policy expectations [10][41] Summary by Sections Market Performance - The rare earth magnetic materials industry has outperformed the CSI 300 index over the past 12 months with a relative return of 47% and an absolute return of 64% [4] - The industry valuation has increased to 74.16, reflecting a recovery in market sentiment [5][12] Price Trends - Rare earth concentrate prices have continued to rise, with mixed carbonate rare earth prices increasing by 2.7% to 3.8 million CNY/ton, and heavy rare earth prices showing a mixed trend [9][12] - Neodymium prices have seen a slight increase followed by a correction, with average prices for neodymium oxide rising by 2.82% to 58.3 million CNY/ton [16] - Dysprosium and terbium prices have continued to decline, with dysprosium oxide prices dropping by 4.41% to 1410 CNY/kg [19] Investment Recommendations - The report suggests maintaining an "Overweight" rating, focusing on upstream rare earth resource companies due to supply tightening and strategic value positioning. Downstream magnetic material companies are also expected to benefit from price recovery [10][43]

Investment Rating - The industry investment rating is maintained as "Buy" [2] Core Views - The food and beverage industry has shown a decline of 1.90% from December 1 to December 5, 2025, underperforming the CSI 300 index by 3.18 percentage points [4][9] - The overall valuation of the food and beverage industry is at a relatively low level, with a PE ratio of 22X, ranking 23rd among Shenwan's primary industries [5][16] - The report emphasizes the importance of focusing on consumer-driven strategies and innovation, as highlighted by the recent global dealer conference of Fenjiu [6] Summary by Sections Industry Performance - From December 1 to December 5, 2025, the food and beverage industry declined by 1.90%, ranking 28th out of 31 sectors, with sub-sectors showing mixed performance [4][9] Valuation Analysis - As of December 5, 2025, the food and beverage industry's PE ratio is 22X, with other liquor at 55X, health products at 36X, and snacks at 35X being the highest valued sub-sectors [5][16] Investment Recommendations - The report suggests focusing on companies with stable demand and strong risk resistance, as well as those actively innovating in new products and channels. Key companies to watch include Miaokelando, Andeli, Shanxi Fenjiu, Guizhou Moutai, and Yanjinpuzi [7][44]

证券研究报告 2025 年 12 月 07 日 湘财证券研究所 行业研究 银行业周报 "双支柱"加强促进银行稳健经营 | 1. | 《2025年中期策略-价值重估仍 | | --- | --- | | 在进行时》 | 2025.07.02 | | 2. | 《业绩底部修复，配置价值提 | | 升》 | 2025.09.05 | | % | 1 | 个月 | 3 | 个月 | 12 | 个月 | | --- | --- | --- | --- | --- | --- | --- | | 相对收益 | -0.6 | | -3.4 | | | -3.1 | | 绝对收益 | -1.5 | | -0.6 | | | 13.8 | 分析师：郭怡萍 证书编号：S0500523080002 Tel：(8621) 50295327 Email：guoyp@xcsc.com 地址：上海市浦东新区银城路88号中 国人寿金融中心10楼 相关研究： 核心要点： 央行推动完善双支柱体系，促进提升银行经营稳健性 2. 《业绩底部修复，配置价值提 行业评级：增持（维持） 央行行长潘功胜发表署名文章《构建科学稳健的货币政策体系和覆盖全面 的 ...

Investment Rating - The report maintains an "Overweight" rating for the securities industry [2][7][26] Core Views - The securities sector is experiencing a recovery in performance expectations, with the price-to-book (PB) ratio having fallen to a low level not seen in the past decade, indicating high allocation value and safety margins [7][26] - The average daily trading volume in the stock market has been declining for three consecutive weeks, with a current average of 16,843 billion yuan, reflecting a 2.4% decrease week-on-week [5][13] - The report highlights that the financing scale for equity financing has increased significantly year-to-date, with a 259% year-on-year growth, indicating robust market activity [17][21] Summary by Sections Market Review - The Shanghai Composite Index rose by 0.4%, while the CSI 300 Index increased by 1.3% during the week of December 1-5, 2025 [4][9] - The non-bank financial index increased by 2.3%, outperforming the CSI 300 by 1 percentage point [4][9] - The broker index rose by 1.1%, slightly underperforming the CSI 300 [4][9] Brokerage Business - The average daily stock trading volume for the two markets was 16,843 billion yuan, down 2.4% week-on-week [5][13] - In November, the average daily trading volume was 18,978 billion yuan, showing a year-on-year decrease of 1.67% and a month-on-month decrease of 11.5% [5][13] Investment Banking Business - Four companies conducted equity financing during the week, raising a total of 12.8 billion yuan, a 19% decrease from the previous week [17][21] - Year-to-date, the total equity financing scale has increased by 259%, with IPO financing up by 94% [17][21] Capital Intermediation Business - As of December 5, the margin financing and securities lending balance reached 24,839 billion yuan, a 0.4% increase week-on-week [6][21] - The financing balance increased to 24,665 billion yuan, maintaining a high level for the year [6][21]

Investment Rating - The report maintains a "Buy" rating for the medical services industry [6][10][63] Core Insights - The medical and health sector is experiencing stable development, but the willingness to pay must be considered due to aging demographics [5][6][60] - The medical services sector has shown a decline in performance, with the medical services sub-sector index down 1.37% this week [2][24] - The PE ratio for the medical services sector is currently at 31.14X, with a recent decrease of 0.48X, while the PB ratio is at 3.14X, down 0.04X from the previous week [4][30] Summary by Sections Industry Performance - The medical and biological sector fell by 0.74%, ranking 21st among 31 primary industries [2][12] - The medical services sub-sector index closed at 6326.63 points, down 1.37% [24][30] Company Performance - Top-performing companies in the medical services sector include Baihua Pharmaceutical (+6.5%), ST Zhongzhu (+5.2%), and Innovation Medical (+2.5%) [3][28] - Underperforming companies include Chengda Pharmaceutical (-12.4%), MediX (-7.1%), and YaoKang Bio (-6.5%) [3][28] Valuation Metrics - The medical services sector's PE ratio is 31.14X, with a one-year maximum of 41.13X and a minimum of 28.46X [4][30] - The PB ratio stands at 3.14X, with a one-year maximum of 4.00X and a minimum of 2.48X [4][30] Market Trends - The report highlights that the aging population is increasing medical demand, but payment willingness is a critical factor [6][62] - The report suggests focusing on leading companies like Aier Eye Hospital and innovative companies in the CXO sector such as WuXi AppTec and Haoyuan Pharmaceutical [9][62]

Group 1: New Materials Industry - The rare earth magnetic materials industry rebounded by 2.6% last week, outperforming the benchmark by 0.96 percentage points, with the industry valuation (TTM P/E) rising to 71.79x, currently at 85.5% of its historical percentile [4] - Last week, the prices of rare earth concentrates generally rebounded, with praseodymium and neodymium prices continuing to rise, dysprosium prices declining, and terbium prices weakening [5] - The price of sintered NdFeB (N35) increased by 3.64% last week, while H35 rose by 2.41%, supported by strong demand from downstream orders [7] - The supply side of the rare earth sector is generally tight, with some separation enterprises experiencing reduced operating rates due to maintenance or raw material issues, leading to a tight supply of oxides [8] - The overall market sentiment is characterized by a standoff, but the supply side is expected to decrease while the demand side shows a steady upward trend, indicating that rare earth prices are likely to remain stable with a slight upward bias [8] Group 2: Medical Services Industry - The report highlights that the company is a leading CDMO (Contract Development and Manufacturing Organization) driven by innovation, with revenue growing from 2.017 billion yuan in 2019 to 5.161 billion yuan in 2024, reflecting a CAGR of 20.67% [11] - The revenue from contract custom business has been increasing, with its share rising from 37.55% in 2019 to 75.00% in 2024, indicating a strong focus on this segment [12] - The global CDMO market has maintained a high level of prosperity, with the market size growing from $44.6 billion in 2018 to $79.7 billion in 2023, and is expected to reach $168.4 billion and $338.5 billion by 2028 and 2030, respectively [14] - The company is actively expanding its project pipeline, particularly in peptide and conjugated nucleic acid technologies, which are expected to drive future growth [15] - The company is projected to achieve revenues of 5.670 billion, 6.278 billion, and 6.957 billion yuan from 2025 to 2027, with corresponding net profits of 930 million, 1.031 billion, and 1.147 billion yuan, indicating a positive long-term outlook [16]

❑ 通用设备：10 月我国工业利润短期承压，静待"反内卷"效果落地 据 Wind，2025 年 1-10 月我国工业企业营业收入同比增长 1.8%，增速较前值下降 0.6pct； 工业企业利润总额同比增长 1.9%，增速较前值下降 1.3pct；其中 10 月当月工业企业利润总额 同比下降 5.5%，主要受上年同期基数有所抬高、财务费用增长较快等因素影响。制造业方面， 据 Wind，2025 年 1-10 月我国制造业营业收入同比增长 2.6%，增速较前值下降 0.8pct；制造 业利润总额同比增长 7.7%，增速较前值下降 2.2pct。总体来看，受工业企业收入增速下降、 工业企业成本费用率上升以及上年同期基数升高等因素影响，10 月我国工业和制造业利润增 速均有所下降。不过，从库存来看，10 月我国工业产成品存货同比增长 3.7%，增速较前值回 升 0.9pct，连续 2 月回升；10 月我国 PPI 增速亦较前值收窄 0.2pct 至-2.1%，连续 3 个月回升， 或表明我国已逐渐进入新一轮补库周期。展望未来，在宏观政策持续发力、叠加"反内卷" 进程持续推进和补库周期开启，我国工业和制造业营业收入和利 ...

- The report discusses the construction of two quantitative models for Hong Kong stock market sector rotation based on southbound capital flows: one adjusted by sector market capitalization and another adjusted by the three-year percentile of sector market capitalization preferences of southbound capital[20][22] - The first model, adjusted by sector market capitalization, aims to capture the recent preferences of southbound capital by normalizing the net inflow of capital into each sector relative to its market capitalization[20] - The second model, adjusted by the three-year percentile of sector market capitalization preferences, seeks to identify long-term trends in sector preferences by calculating the historical percentile rank of capital inflows into each sector over the past three years[20] - Both models are tested against the Hang Seng Index and equal-weighted sector portfolios, demonstrating the ability to generate excess returns[22]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for future performance [6][7]. Core Insights - The company is positioned as an innovative leader in the CDMO (Contract Development and Manufacturing Organization) sector, focusing on providing customized R&D and manufacturing services for pharmaceutical and biotech companies globally. The company's revenue has shown a compound annual growth rate (CAGR) of 20.67% from 2019 to 2024, with a projected revenue of 51.61 billion yuan in 2024 [1][3]. - The company's contract manufacturing revenue has significantly increased, accounting for 75% of total revenue in 2024, with international revenue making up 79.12% of total sales [2][3]. - The global CDMO market is experiencing robust growth, with an expected market size of $168.4 billion by 2028 and $338.5 billion by 2030, which the company is well-positioned to benefit from [3][4]. Summary by Sections Financial Performance - The company's revenue increased from 20.17 billion yuan in 2019 to 51.61 billion yuan in 2024, with a net profit growth from 2.38 billion yuan in 2019 to 10.33 billion yuan in 2023. However, net profit in 2024 was impacted by non-recurring losses, dropping to 6.06 billion yuan, a decrease of 41.34% year-on-year. In Q1-Q3 2025, net profit rebounded to 7.48 billion yuan, up 18.51% year-on-year [1][7]. Business Strategy - The company has a clear strategic focus on innovative drug CDMO services, with a growing pipeline of projects in peptide and conjugated nucleic acid technologies. The company is expanding its production capacity for peptides to 800 kg/year and is establishing commercialization capabilities for small nucleic acids [4][7]. Market Outlook - The report highlights the high market demand for innovative drugs, which is driving the growth of the CDMO sector. The company is expected to benefit from this trend, with projected revenues of 56.70 billion yuan, 62.78 billion yuan, and 69.57 billion yuan for 2025, 2026, and 2027, respectively [7][9].